Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Interferon beta-1a, Fertigarzneimittelbezeichnung Rebif(R), ATC L03AB07
Opportunity Score
Confidence: 30%
Complexity: medium
719 days
Deadline
supplies
Contract
Deep Portfolio Analysis
- Company fit score
- Missing certificates
- Eligibility blockers
- Bid / No-Bid recommendation
AI Analysis Summary
This is an open-house model for non-exclusive discount agreements on Interferon beta-1a (Rebif) with AOK Bayern. All eligible pharmaceutical companies can join at any time during the contract period (01.08.2026 – 31.07.2028) by signing a standard agreement and providing a declaration of reliability. No competitive selection; each qualified company gets a contract. The tender is not subject to procurement law according to the notice.
Strengths
Documents available
Open procedure
Medium complexity
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
- Must be a pharmaceutical enterprise
- Submit a signed and completed declaration of reliability
- Submit the signed contract agreement and the appendix 'Festlegung der vertragsgegenständlichen Arzneimittel'
Buyer
Name
AOK Bayern - Die Gesundheitskasse
Location
München, DEU
Identifier
DE811695320
Lots (1)
Non-exclusive discount agreements for the active substance Interferon beta-1a (Rebif). Contracts are identical and not individually negotiated. Performance in Bavaria, Germany.
Procurement Details
Publication
14 Jun 2026
Deadline
03 Jun 2028, 10:00
Procedure
open
Contract
supplies
Language
DEU
Publication #
406578-2026
Classification
Performance: Germany
Documents (2)
Opportunity Score
Confidence: 30%
Complexity: medium
719 days
Deadline
supplies
Contract
Deep Portfolio Analysis
- Company fit score
- Missing certificates
- Eligibility blockers
- Bid / No-Bid recommendation